Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - hydrochlorothiazide; losartan potassium - film-coated tablet - 100 mg/12.5 milligram(s) - losartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - hydrochlorothiazide; losartan potassium - film-coated tablet - 100/12.5 milligram(s) - angiotensin ii antagonists and diuretics; losartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - hydrochlorothiazide; losartan potassium - film-coated tablet - 50 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; losartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - losartan potassium - film coated tablet - 12.5 milligram - angiotensin ii antagonists, plain

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - losartan potassium - film coated tablet - 50 milligram - angiotensin ii antagonists, plain

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; glycerol dibehenate; magnesium stearate; povidone; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; glycerol dibehenate; maize starch; sodium starch glycollate type a; magnesium stearate; povidone; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; glycerol dibehenate; povidone; maize starch; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; glycerol dibehenate; povidone; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - bosentan monohydrate, quantity: 129.083 mg - tablet, film coated - excipient ingredients: glycerol dibehenate; povidone; pregelatinised maize starch; magnesium stearate; sodium starch glycollate type a; maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms